University Hospitals Birmingham NHS Foundation Trust

Status Drug name NICE TAs Comments
Status: Red Ritlecitinib
Status: Red Ritumixab infusion (Mabthera®, Truxima®)
Status: Red Rituximab
Status: Amber Rivaroxaban tablets
  • Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants
  • Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
  • Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
Status: Red Rivaroxaban tablets #2.8

BSSE APC preferred agent. This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use.

Red use following hip and knee surgery – full course of treatment supplied on discharge

Status: Amber Rivastigmine capsules

Dementia drugs ESCA

Status: Amber Rivastigmine patches

Dementia drugs ESCA

Status: Green Rizatriptan tablets

Reserved for patients who are vomiting due to migraine

Status: Red Rocuronium injection
Status: Amber Roflumilast (Daxas)

To be use in line with NICE. Supported with a RICaD

Building healthier lives
Back to top